409 related articles for article (PubMed ID: 30891617)
1. Innate immune regulatory networks in hepatic lipid metabolism.
Bai L; Li H
J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617
[TBL] [Abstract][Full Text] [Related]
2. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
3. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
[TBL] [Abstract][Full Text] [Related]
4. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.
Chen Z; Yu Y; Cai J; Li H
Trends Endocrinol Metab; 2019 Dec; 30(12):903-914. PubMed ID: 31597607
[TBL] [Abstract][Full Text] [Related]
5. 'Micro-managers' of hepatic lipid metabolism and NAFLD.
Liu W; Cao H; Yan J; Huang R; Ying H
Wiley Interdiscip Rev RNA; 2015; 6(5):581-93. PubMed ID: 26198708
[TBL] [Abstract][Full Text] [Related]
6. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
Cai J; Zhang XJ; Li H
Trends Endocrinol Metab; 2018 Oct; 29(10):712-722. PubMed ID: 30131212
[TBL] [Abstract][Full Text] [Related]
7. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis.
Houben T; Brandsma E; Walenbergh SMA; Hofker MH; Shiri-Sverdlov R
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):416-429. PubMed ID: 27472963
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
Ipsen DH; Lykkesfeldt J; Tveden-Nyborg P
Cell Mol Life Sci; 2018 Sep; 75(18):3313-3327. PubMed ID: 29936596
[TBL] [Abstract][Full Text] [Related]
9. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
Xi Y; Li H
Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
[TBL] [Abstract][Full Text] [Related]
10. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
11. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.
Cai J; Xu M; Zhang X; Li H
Annu Rev Pathol; 2019 Jan; 14():153-184. PubMed ID: 30230967
[TBL] [Abstract][Full Text] [Related]
12. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
13. A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD.
Ashworth WB; Davies NA; Bogle ID
PLoS Comput Biol; 2016 Sep; 12(9):e1005105. PubMed ID: 27632189
[TBL] [Abstract][Full Text] [Related]
14. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
16. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
17. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
18. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.
Badmus OO; Hillhouse SA; Anderson CD; Hinds TD; Stec DE
Clin Sci (Lond); 2022 Sep; 136(18):1347-1366. PubMed ID: 36148775
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
